An observational study to evaluate chemotherapy induced nausea and vomiting control in non-Hodgkin lymphoma patients receiving R-CHOP

Australasian Leukaemia and Lymphoma Group0 个研究点目标入组 100 人开始时间: 2011年12月12日最近更新: 2020年1月13日

试验速览

暂无简介。

•Chemotherapy-naive or those who have not received chemotherapy in the last 12 months;
•Histologically confirmed diagnosis of NHL;
•Intended to receive (R)-CHOP every 14 or 21 days for a minimum of 3 cycles;
•Able to provide informed consent;
•Are reasonably expected to be able to complete the CINV diary.

•Women who are pregnant or lactating;
•Previous exposure to chemotherapy, excluding oral alkylator therapy or single agent rituximab more than 12 months previously;
•Prior radiotherapy within 12 months;
•Use of concomitant medication with Orap (pimozide), Seldane (terfenadine), Hismanal (astemizole), or Propulsid (cisapride);
•Any other clinically important abnormalities as determined by the investigator that may interfere with his or her participation in or compliance with the study;
•Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. This condition must be discussed with the patient prior to signing consent and registration in the trial;
•Age < 18 years.

发起方

Australasian Leukaemia and Lymphoma Group